ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

XLO Xilio Therapeutics Inc

1.07
0.06 (5.94%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Xilio Therapeutics Inc XLO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.06 5.94% 1.07 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.02 1.02 1.11 1.09 1.01
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/4/202415:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
28/3/202406:05GLOBEXilio Therapeutics Announces $11.3 Million Private Placement..
28/3/202406:00BWGilead and Xilio Announce Exclusive License Agreement for..
28/2/202415:01GLOBEXilio Therapeutics to Participate in Novel Immuno-Oncology..
31/1/202415:01GLOBEXilio Therapeutics to Present at Guggenheim 6th Annual..
19/1/202415:30EDGAR2Form 8-K - Current report
08/1/202406:30GLOBEXilio Therapeutics Highlights Recent Advances Across..
03/1/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:05EDGAR2Form 8-K - Current report
07/12/202306:45EDGAR2Form 8-K - Current report
07/12/202306:30GLOBEXilio Therapeutics Announces Initiation of Enrollment for..
09/11/202315:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:13EDGAR2Form 8-K - Current report
09/11/202315:10EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
09/11/202315:08EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
09/11/202315:05EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
09/11/202315:01GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
03/11/202315:05EDGAR2Form 8-K - Current report
03/11/202311:00GLOBEXilio Announces Initial Monotherapy Safety and Anti-Tumor..
31/10/202308:15GLOBEXilio to Host Virtual Investor Conference Call and Webcast..
27/9/202316:02GLOBEXilio Therapeutics Announces Upcoming Presentations at the..
07/9/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202315:23EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202307:35EDGAR2Form 8-K - Current report
05/9/202307:30GLOBEXilio Therapeutics Announces Promotion of Katarina..
05/9/202306:30GLOBEXilio Therapeutics to Present at Morgan Stanley 21st Annual..
18/8/202319:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202319:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202306:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202306:40EDGAR2Form 8-K - Current report
14/8/202306:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
07/8/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202315:09EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/8/202315:15EDGAR2Form 8-K - Current report
03/8/202315:05GLOBEXilio Therapeutics Announces Promotion of Chris Frankenfield..
25/5/202316:01GLOBEXilio Therapeutics Announces Preliminary Clinical Data from..
09/5/202306:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..

Su Consulta Reciente

Delayed Upgrade Clock